This report analyzes the future of salt reduction, assesses existing and future technologies and ingredients to reduce sodium content and provides company analysis and product examples of salt reduced, low salt and no-salt brands.

Salt reduction has become a key issue for consumers, governments, and manufacturers, creating an opportunity and challenge for manufacturers to create reduced salt or sodium offerings. In addition, sodium or salt labeling is likely to become mandatory in most regions. This report analyzes the market context, NPD landscape, new ingredients and technologies and future salt reduction strategies.

Scope of this research

• Understand the key drivers for salt reduction in food and drinks with a specific focus on new developments.
• Evaluate new product launches with reduced salt type claims, and the activities of key food and drink manufacturers leading product innovation.
• Identify and assess new ingredients and technologies which are expanding the boundaries of what can be achieved in salt reduction in food and drinks.
• Analyze innovative tools being used in the research and development of salt reduction solutions.
• Understand the opinions of key stakeholders and the future opportunities and challenges for the food and drinks manufacturers.

Research and analysis highlights

In the industry survey carried out for this report, the six most mentioned (all receiving at least 5% of total mentions) companies/brands thought to be driving innovation within the reduction of salt and sodium in food and drink were the Campbell Soup Company, Nestlé, Unilever, Kraft, Frito-Lay, and Heinz.

Between 2007 and 2010, approximately 3.7% of new ‘reduced salt type’ food and non-alcoholic drinks products listed potassium chloride as an ingredient. 1.6% of all new products between 2007 and 2010 featured a ‘reduced salt type’ claim . This compares to a rate of 7.9% for ‘reduced fat type’ launches, and 5.1% for ‘reduced sugar type’ launches.

The categories accounting for the highest shares of new ‘reduced salt type’ food and drinks 2007-2010 were bakery and cereals; sauces, dressings and condiments; and soft drinks. These categories accounted for more than 50% of ‘reduced salt type’ new products in the period between them.

Key reasons to purchase this research

• What are the market drivers for salt reduction and how will these affect salt reduction targets, target market focus, labeling and claims regulations.
• What is the overall rate of NPD with reduced salt type features and which categories have the highest share of low/no salt new products?
• What are the new products and research activities of some of the largest food and drink manufacturers in the area of salt reduction?
• Which new ingredients and technologies are allowing for greater levels of successful salt substitution?
• What are the key opportunities and challenges for manufacturers within the area of salt reduction in food and drinks?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/16205/Innovations-in-Salt-Reduction-in-Food-and-Drinks-New-products-ingredients-and-technologies.html

This Kalorama Information report – Clinical Nutrition – focuses on three primary segments of essential medical nutrition:

• Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort)
• Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients)
• Parenteral Nutrition

For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall global population. Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets. The market segments provide an overview, description of products on the market, new developments, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

Coverage of Issues and Trends in Clinical Nutrition

There are several issues and trends that are impacting the clinical nutrition market, including:

• Wound Care Applications
• Reimbursement of Nutrition Products
• Food Programs
• Nutrition and Education
• DHA and ANA Additives
• Counterfeit Infant Formulas
• Recalled Infant Formulas
• Acquisition, Mergers and Alliances
• Technology Applications

A Growing Market with Thriving Competition

Competition in the clinical nutrition market is dominated by a handful of companies, ranging from global nutritional manufacturers to leading pharmaceutical companies. The majority of competitive participation is in developed regions such as the United States, Western Europe, and Japan. However, many companies are expanding into less developed regions, intensifying competition in less tapped markets. China, for example, is among the expanding competitive regions as companies continue to break into the growing demand for clinical nutrition in new world markets. Companies highlighted in this study include:

• Abbott Laboratories
• Baxter International
• B. Braun
• Danone
• Fresenius Kabi
• Mead Johnson
• Nestle
• PBM Products
• Wyeth

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 80 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with nutrition company representatives included marketing directors, division managers, and product representatives. All market data pertains to the world market at the manufacturers’ level.

The base year for data was 2008. Historical data was provided for the years 2006 and 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2006-2008, 2008-2013 and 2006-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on demographic trends, new developments, and global expansion.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1626/Clinical-Nutrition-Products-World-Markets-3rd-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China’s blood products has soared up and corporate profitability also has increased significantly.

China’s blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy.

The report makes an in-depth analysis of the status quo of China’s blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China’s seven key blood product companies, such as Hualan Biological Engineering Inc.

As a key company of blood products R&D and production in China, the revenue of Hualan Biological Engineering Inc achieved RMB475 million in 2008, up 35.32% year-on-year; and the total profit was RMB218 million, a 69.73% YoY rise. Moreover, the current and newly-built plasma collection stations primarily distribute in Guizhou, Guangxi and Chongqing. Up to 2008, it had owned 11 plasma collection stations, and three under construction. It has eased the short supply of plasma via building new plasma collection stations.

Hualan Biological Engineering has taken the lead in blood products field in China, in the meantime, it has accessed into vaccine sector actively. It was the first to obtain Influenza A strain on Jun 8, 2009, and it entered the clinical trials on July 22. The monthly output capacity of Influenza A vaccine can reach 7.5 million units, and it would carry the reserves of 4 million units before Sep 15. Besides, it had produced 13 million units of Influenza A vaccine before Oct 1. As is estimated, it can supply 35-40 million units of Influenza A vaccine by the end of 2009.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1019/China-Blood-Products-Industry-Report-2009.html

Contact us:

Visionshopsters
Ph : +91-22-40583000
Emailid:  marketing@visionshopsters.com
Website : www.visionshopsters.com